Metabolic shares suspended

By Ruth Beran
Friday, 10 June, 2005

Melbourne based Metabolic Pharmaceuticals (ASX:MBP) has suspended its shares from the ASX's official quotation in the lead-up to an announcement.

This follows a trading halt on June 8, and a recent clarification by the company of a previously announced Phase IIb trial of its anti-obesity drug AOD9604 to determine optimal dosage.

AusBiotech partners with Tenmile

Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...

Australian CDC issues update in wake of Ebola outbreak

After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...

Australia announces $7.2m diphtheria outbreak response package

To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...

Content from other channels on our network

Siemens expands Fusesaver manufacturing facility

BESS project provides long-duration battery for NSW

Lessons in long-distance telemetry

GECA and ACOR launch national standard for recycling

Antibiotics in wastewater may contribute to antimicrobial resistance

New Energy Transport secures funding to accelerate electric road freight

Siemens expands Queensland manufacturing facility

Customer demand exceeding capacity for Alpha HPA

Curtin University project to research sustainable gallium processing

How to extend the life of your motor bearings

Unify risk and compliance to protect patients.

Australian health care's burnout prescription

"Fake podiatrist" jailed after hundreds of consultations with vulnerable patients

Unlocking the potential of our nursing workforce

National Model for Clinical Governance now available